Johnson & Johnson - Net Worth and Insider Trading

Johnson & Johnson Net Worth

The estimated net worth of Johnson & Johnson is at least $205 Million dollars as of 2024-05-05. Johnson & Johnson is the 10% Owner of Fusion Pharmaceuticals Inc and owns about 3,670,516 shares of Fusion Pharmaceuticals Inc (FUSN) stock worth over $79 Million. Johnson & Johnson is the 10% Owner of Protagonist Therapeutics Inc and owns about 2,449,183 shares of Protagonist Therapeutics Inc (PTGX) stock worth over $64 Million. Johnson & Johnson is also the 10% Owner of CVRx Inc and owns about 4,103,430 shares of CVRx Inc (CVRX) stock worth over $38 Million. Besides these, Johnson & Johnson also holds Nevro Corp (NVRO) , Minerva Neurosciences Inc (NERV) , Neoleukin Therapeutics Inc (NLTX) , Achillion Pharmaceuticals Inc (ACHN) . Details can be seen in Johnson & Johnson's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Johnson & Johnson has not made any transactions after 2024-02-16 and currently still holds the listed stock(s).

Transaction Summary of Johnson & Johnson

To

Johnson & Johnson Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Johnson & Johnson owns 18 companies in total, including Fusion Pharmaceuticals Inc (FUSN) , Provention Bio Inc (PRVB) , and Inspire Medical Systems Inc (INSP) among others .

Click here to see the complete history of Johnson & Johnson’s form 4 insider trades.

Insider Ownership Summary of Johnson & Johnson

Ticker Comapny Transaction Date Type of Owner
FUSN Fusion Pharmaceuticals Inc 2020-06-30 10 percent owner
PRVB Provention Bio Inc 2018-07-03 10 percent owner
INSP Inspire Medical Systems Inc 2018-05-02 10 percent owner
2017-11-20 10 percent owner
2015-03-13 10 percent owner
2016-08-16 10 percent owner
2015-06-08 10 percent owner
2015-08-11 10 percent owner
2014-05-01 10 percent owner
2014-02-04 10 percent owner
2010-12-31 10 percent owner
2010-04-14 10 percent owner
2007-03-27 10 percent owner
2003-12-31 10 percent owner
2024-02-16 10 percent owner
2022-11-09 10 percent owner
2014-02-04 10 percent owner
2023-05-03 10 percent owner

Johnson & Johnson Latest Holdings Summary

Johnson & Johnson currently owns a total of 7 stocks. Among these stocks, Johnson & Johnson owns 3,670,516 shares of Fusion Pharmaceuticals Inc (FUSN) as of June 30, 2020, with a value of $79 Million and a weighting of 38.38%. Johnson & Johnson owns 2,449,183 shares of Protagonist Therapeutics Inc (PTGX) as of August 16, 2016, with a value of $64 Million and a weighting of 31.15%. Johnson & Johnson also owns 4,103,430 shares of CVRx Inc (CVRX) as of February 16, 2024, with a value of $38 Million and a weighting of 18.44%. The other 4 stocks Nevro Corp (NVRO) , Minerva Neurosciences Inc (NERV) , Neoleukin Therapeutics Inc (NLTX) , Achillion Pharmaceuticals Inc (ACHN) have a combined weighting of 12.03% among all his current holdings.

Latest Holdings of Johnson & Johnson

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
FUSN Fusion Pharmaceuticals Inc 2020-06-30 3,670,516 21.45 78,732,568
PTGX Protagonist Therapeutics Inc 2016-08-16 2,449,183 26.09 63,899,184
CVRX CVRx Inc 2024-02-16 4,103,430 9.22 37,833,625
NVRO Nevro Corp 2015-06-08 2,066,740 11.29 23,333,495
NERV Minerva Neurosciences Inc 2015-03-13 562,520 2.37 1,333,172
NLTX Neoleukin Therapeutics Inc 2015-08-11 5,000 3.49 17,450
ACHN Achillion Pharmaceuticals Inc 2017-11-20 0 6.76 0

Holding Weightings of Johnson & Johnson


Johnson & Johnson Form 4 Trading Tracker

According to the SEC Form 4 filings, Johnson & Johnson has made a total of 1 transactions in Fusion Pharmaceuticals Inc (FUSN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Fusion Pharmaceuticals Inc is the acquisition of 725,000 shares on June 30, 2020, which cost Johnson & Johnson around $12 Million.

According to the SEC Form 4 filings, Johnson & Johnson has made a total of 0 transactions in Protagonist Therapeutics Inc (PTGX) over the past 5 years. The most-recent trade in Protagonist Therapeutics Inc is the acquisition of 583,333 shares on August 16, 2016, which cost Johnson & Johnson around $7 Million.

According to the SEC Form 4 filings, Johnson & Johnson has made a total of 1 transactions in CVRx Inc (CVRX) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in CVRx Inc is the sale of 3,725 shares on February 16, 2024, which brought Johnson & Johnson around $96,142.

More details on Johnson & Johnson's insider transactions can be found in the Insider Trading History of Johnson & Johnson table.

Insider Trading History of Johnson & Johnson

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Johnson & Johnson Trading Performance

GuruFocus tracks the stock performance after each of Johnson & Johnson's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Johnson & Johnson is 27.87%. GuruFocus also compares Johnson & Johnson's trading performance to market benchmark return within the same time period. The performance of stocks bought by Johnson & Johnson within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Johnson & Johnson's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Johnson & Johnson

Average Return

Average return per transaction

Outperforming Transactions

2 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 0.7
Relative Return to S&P 500(%) -0.9

Johnson & Johnson Ownership Network

Ownership Network List of Johnson & Johnson

No Data

Ownership Network Relation of Johnson & Johnson


Johnson & Johnson Owned Company Details

What does Fusion Pharmaceuticals Inc do?

Who are the key executives at Fusion Pharmaceuticals Inc?

Johnson & Johnson is the 10 percent owner of Fusion Pharmaceuticals Inc. Other key executives at Fusion Pharmaceuticals Inc include Chief Medical Officer Dmitri Bobilev , director & Chief Executive Officer John Valliant , and Chief Scientific Officer Christopher P Leamon .

Fusion Pharmaceuticals Inc (FUSN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Fusion Pharmaceuticals Inc (FUSN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Fusion Pharmaceuticals Inc (FUSN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Fusion Pharmaceuticals Inc (FUSN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Fusion Pharmaceuticals Inc Insider Transactions

No Available Data

Johnson & Johnson Mailing Address

Above is the net worth, insider trading, and ownership report for Johnson & Johnson. You might contact Johnson & Johnson via mailing address: One Johnson & Johnson Plz, New Brunswick Nj 08933.

Discussions on Johnson & Johnson

No discussions yet.